Catalogs >
GE Healthcare Life Sciences >
Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes
5Pages

Catalog excerpts

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes - 1

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs. cytiva.com GE and the GE Monogram are trademarks of General Electric Company. Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva’s portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information. For local office contact information, visit cytiva.com/contact

Open the catalog to page 1

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes - 2

GE Healthcare Life Sciences Application note 29-0929-38 AA Cell expansion Equivalent performance of Xuri™ Cell Expansion System W25 and WAVE Bioreactor™ System 2/10 for the culture of T lymphocytes This Application note describes a robust process for manufacturing human T cells using WAVE Bioreactor System 2/10 and Xuri Cell Expansion System W25. Data presented here demonstrate that the growth rate of T cells on both systems were comparable. In addition, the expanded T cells were phenotypically similar in terms of their differentiation state, and were biologically functional, as...

Open the catalog to page 2

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes - 3

Perfusion rate (ml/24 h) Experiment A Experiment B The perfusion rates were set to ensure that ammonium levels were maintained below 2.0 mmol/l, lactate levels were maintained below 2.0 g/l, and glucose levels were above 1.0 g/l. The media perfusion program on WAVE 2/10 is run as semicontinuous, with shot volumes of 50 ml evenly spaced throughout a 24 h period. For example, a perfusion rate of 500 ml/24 h equates to the removal and replacement of 50 ml approximately every 144 min (or 10 times throughout the 24 h period). Xuri W25 is designed to routinely run perfusion as a continuous...

Open the catalog to page 3

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes - 4

WAVE Bioreactor System 2/10 Xuri Cell Expansion System W25 Fig 4. Expression of costimulatory molecules CD28 and CD27 in CD3+ T cells using WAVE 2/10 and Xuri W25 systems. Representative dot plots are shown at day 0 and at day 10 of culture. Lymphocytes were gated based on their forward- and side-scattter profile. (A) Percentage CD28+CD27+ within CD3+CD4+ T cells. (B) Percentage CD28+CD27+ within CD3+CD8+ T cells. WAVE Bioreactor System 2/10 Day 10 Xuri Cell Expansion System W25 Day 10 Continuous activation and proliferation can drive T cells to a state of senescence, which can be detected...

Open the catalog to page 4

Equivalent performance of Xuri Cell Expansion System W25 and WAVE Bioreactor System 2/10 for the culture of T lymphocytes - 5

To ensure that the expanded cells were still biologically functional at the end of the 10 d culture period, the cells were reactivated with CD3/CD28 beads for 18 to 20 h and cytokine production was measured. The secretion of both Th1 (IFNγ, GM-CSF, TNFα, and IL-2) and Th2 (IL-4, IL-5, and IL-10) cytokines was analyzed. There was no difference in the amounts of cytokine secreted when comparing cultures from WAVE 2/10 and Xuri W25. It was also noted that a Th1 cytokine profile was dominant, which favors a cell-mediated immune response in vivo (Fig 6). WAVE Bioreactor System 2/10 Secreted...

Open the catalog to page 5